COLLPLANT HOLDI/S (CLGN) versus Histogenics (HSGX) Head-To-Head Analysis
COLLPLANT HOLDI/S (NASDAQ:CLGN) and Histogenics (NASDAQ:HSGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.
Earnings and Valuation
This table compares COLLPLANT HOLDI/S and Histogenics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|COLLPLANT HOLDI/S||$480,000.00||34.13||-$6.02 million||($2.26)||-2.12|
This table compares COLLPLANT HOLDI/S and Histogenics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
0.7% of COLLPLANT HOLDI/S shares are owned by institutional investors. Comparatively, 16.9% of Histogenics shares are owned by institutional investors. 19.7% of Histogenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for COLLPLANT HOLDI/S and Histogenics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
COLLPLANT HOLDI/S presently has a consensus price target of $7.00, suggesting a potential upside of 46.14%. Histogenics has a consensus price target of $3.17, suggesting a potential upside of 1,757.28%. Given Histogenics’ higher probable upside, analysts plainly believe Histogenics is more favorable than COLLPLANT HOLDI/S.
Histogenics beats COLLPLANT HOLDI/S on 8 of the 12 factors compared between the two stocks.
About COLLPLANT HOLDI/S
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.